No Data
No Data
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare...
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
Bluebird Bio Announces CFO Transition and Compensation Details
Bluebird Bio Says Continuing To Work Expeditiously To Complete Delayed Filings
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a resu
Express News | Bluebird bio Inc - Appointed Chief Financial Officer (CFO), Effective June 10, 2024
Express News | Bluebird bio Appoints O. James Sterling as Chief Financial Officer
No Data
MARKET-TEST-DUMMY : Seems like more time is needed but heading on the right path to getting patients in line. They seem optimistic as far as the company goes. I'm sure there's a lot of bureaucracy and red tape to getting payments. Like anything else, it should get easier as they go or as they set precedent, so it seems. Not all QTC's are equal and interesting some don't want to be listed on their website though. Wonder if that's a product thing or just not in need of an another patient. Either way, appreciate ya pointing this out. Will be keeping eye on this one too.
TrytosaveabitOP MARKET-TEST-DUMMY: You’re very welcome! Where ya been. I was thinking wow his work musta really picked up. Well at least I’m hoping it was that and nothings gone bad! Anyways good to see ya